Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies

Inflammatory Bowel Diseases

Volumn 18, Issue 9, 2012, Pages 1628-1633

  Kopylov, Uri ^a   Mazor, Yoav ^b,c   Yavzori, Miri ^a   Fudim, Ella ^a   Katz, Lior ^a   Coscas, Daniel ^a   Picard, Orit ^a   Chowers, Yehuda ^b,c   Eliakim, Rami ^a   Ben Horin, Shomron ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b Rambam Health Care Campus ^*  (Israel)

^c Technion   (Israel)

Author keywords

anti infliximab antibodies; anti TNF antibodies; Crohn's disease; infliximab; ulcerative colitis

Indexed keywords

IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN LAMBDA CHAIN ANTIBODY; INFLIXIMAB; INFLIXIMAB ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ACCURACY; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DOUBLE ANTIGEN ENZYME LINKED IMMUNOSORBENT ASSAY; DRUG BLOOD LEVEL; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOGLOBULIN LAMBDA CHAIN ANTIBODY ENZYME LINKED IMMUNOSORBENT ASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PERFORMANCE; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN LAMBDA-CHAINS; INFLAMMATORY BOWEL DISEASES;

EID: 84864990946     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21919     Document Type: Article

References (14)

1. Hanauer S, Feagan B, Lichtenshtein G, et al. Maintenance infliximab for Crohn's Disease: the ACCENT 1 randomized trial. Lancet. 2002; 359: 1541-1549.
2. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004; 350: 876-885.
3. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut. 2009; 58: 492-500.
4. Gisbert JP, Panes J,. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009; 104: 760-767.
5. Ben-Horin S, Chowers Y,. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 2011; 33: 987-995.
6. Baert F, Noman M, Vermeire S, Van Assche G, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348: 601-608.
7. Ben-Horin S, Yavzori M, Katz L, et al. The immunogenic part of infliximab lies within the Fab fragment, but measurement of antibodies against the intact infliximab molecule shows superior clinical usefulness. Gut. 2011; 60: 41-48.
8. Colombel JF, Sandborn WJ, Reinisch W, et al. SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362: 1383-1395.
9. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010; 59: 49-54.
10. Ainsworth MA, Bendtzen K, Brynskov J,. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol. 2008; 103: 944-948.
11. Wolbink GJ, Vis M, Lems W, Voskuyl AE, et al. Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006; 54: 711-715.
12. Klotz U, Teml A, Schwab M,. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007; 46: 645-660.
13. Maser E, Villela R, Silverberg M, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006; 4: 1248-1254.
14. Kopylov U, Mantzaris GJ, Katsanos KH, et al. The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. Aliment Pharmacol Ther. 2011; 33: 349-357.